Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of SCTB35 + GemOx versus rituximab + GemOx in relapsed/refractory diffuse large B-cell lymphoma
CTR20262058Phase 3Active
- Sponsor
- Sinocelltech Group Limited
- Start
- Jun 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of SCTB35 in diffuse large B-cell lymphoma (DLBCL), sponsored by Sinocelltech Group Limited. Started Jun 2026; status: active.
02
Drugs
SCTB35
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on CTR20262058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262058.